Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
26
-
Total 13F shares, excl. options
-
1,867,615
-
Shares change
-
+296,396
-
Total reported value, excl. options
-
$7,040,313
-
Value change
-
+$1,135,475
-
Put/Call ratio
-
72.07%
-
Number of buys
-
14
-
Number of sells
-
-9
-
Price
-
$3.77
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q1 2024
33 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q1 2024.
Gain Therapeutics, Inc. - COM (GANX) has 26 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,867,615 shares
.
Largest 10 shareholders include DME Capital Management, LP (566,130 shares), RAYMOND JAMES & ASSOCIATES (260,019 shares), Royal Bank of Canada (248,500 shares), GEODE CAPITAL MANAGEMENT, LLC (177,091 shares), VANGUARD GROUP INC (119,364 shares), CM Management, LLC (90,000 shares), BlackRock Inc. (75,398 shares), RENAISSANCE TECHNOLOGIES LLC (46,700 shares), NORTHERN TRUST CORP (46,486 shares), and MILLENNIUM MANAGEMENT LLC (44,416 shares).
This table shows the top 26 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.